# Effects of Acute and Chronic Empagliflozin Heart Failure

> **NCT05553938** · PHASE1 · RECRUITING · sponsor: **Yale University** · enrollment: 60 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Empagliflozin 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05553938
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-04
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05553938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05553938, "Effects of Acute and Chronic Empagliflozin Heart Failure". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05553938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*